BCL2L1 and cancer: Combining chemotherapy with the silencing of BCL-xL significantly increased cancer cell death from less than 20% to 60–70%, while silencing MCL-1 or BCL-2 had no substantial impact on sensitivity to chemotherapy (Fig. 2B).